All In Biotech

Drug Trial Radar · NCT03716427

Drug Interaction Study of CT1812 in Healthy Volunteers

A Fixed-Sequence Trial to Examine the Effect of Multiple-Dose CT1812 Administration on Standard Probes of CYP2C19 (Omeprazole), CYP2C9 (Tolbutamide), CYP2D6 (Dextromethorphan), and CYP3A4/5 (Midazolam) Activity in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Nov 10, 2016

Primary completion

Dec 27, 2016

Study completion Feb 15, 2017

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).

Conditions

  • Healthy Volunteers

Interventions

  • CT1812Drug

  • tolbutamideDrug

    Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide

  • dextromethorphanDrug

    Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan

  • OmeprazoleDrug

    Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole

  • midazolamDrug

    Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma-concentration time curve of CT1812 (Day 6) compared to the baseline values (Day -2)Time frame: 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jasper Clinic

    Kalamazoo, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.